Sun Pharma’s $11.75 Billion Deal With Organon Explained

Sun Pharmaceutical Industries Ltd. on Monday announced the acquisition of New York-listed Organon & Co. in an all‑cash
transaction with an enterprise valuation of $11.75 billion. The Indian drugmaker will buy all outstanding shares for $14 per share in cash, or approximately $3.99 billion in total equity value, according to a stock exchange filing. In this video. In this video, Managing Director of the company, Dilip Shanghvi reveals the reasons behind this big deal. Watch now!

#sunpharma #organon #pharma #pharmaceutical
For more videos subscribe to our channel: https://www.youtube.com/@NDTVProfitIndia
Visit NDTV Profit for more news: https://www.ndtvprofit.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-reports

Follow NDTV Profit here
Twitter: https://twitter.com/NDTVProfitIndia , https://twitter.com/NDTVProfit
LinkedIn: https://www.linkedin.com/company/ndtvprofit
Instagram: https://www.instagram.com/ndtvprofit/
Facebook: https://www.facebook.com/NDTVProfit/

Producer: Rishika Kashyap
Anchor: Varsha Chandnani
--
#NDTVProfitVideo
--
#Business

Видео Sun Pharma’s $11.75 Billion Deal With Organon Explained канала NDTV Profit